Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection
Open Access
- 30 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 51 (8), 1520-1521
- https://doi.org/10.1093/rheumatology/kes051
Abstract
Sir, Immunosuppressive therapy with biologics in patients with RA and concomitant infection with HCV is a challenge in clinical practice. Tocilizumab (TCZ) is a humanized mAb directed towards the IL-6 receptor that has become a novel treatment option for RA. Here we report on an RA patient with chronic HCV infection who received TCZ during an 12-month follow-up period.This publication has 7 references indexed in Scilit:
- Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic reviewRheumatology, 2011
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trialsRheumatology, 2010
- Glucocorticosteroids Increase Cell Entry by Hepatitis C VirusGastroenterology, 2010
- Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathyRheumatology International, 2009
- Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysisLiver Transplantation, 2006
- Interleukin 6 and liver regenerationGut, 2000
- Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapyArthritis & Rheumatism, 2000